A slowdown in overall spending was driven, in part, by reduced growth in spending on prescription drugs. In 2014, spending on these drugs grew by 12.4%; this pace saw just 0.4% growth in 2017.
According to data newly released by CMS’ Office of the Actuary, national health spending overall grew at a rate of 3.9%—to $3.5 trillion—in 2017, a rate that is almost a full percentage point slower than 2016 growth.
The slowdown in overall spending was driven, in part, by reduced growth in spending on prescription drugs. In 2014, spending on retail prescription drugs grew by 12.4%, and in 2015, spending grew by a still-substantial 8.9%, largely on the basis of increased spending on high-cost therapies such as those that treat hepatitis C. This growth slowed to 2.3% in 2016 and just 0.4% in 2017.
According to CMS, in a paper published in Health Affairs,1 this slowdown is primarily due to reduced growth in the number of prescriptions that are being dispensed, as well as a continued shift toward the use of lower-cost products and declines in the cost of generic drugs. Other factors include slower growth in the volume of some high-cost products and lower price hikes for brand-name products.
Other areas of healthcare that saw slowdowns in 2017 included hospital spending, which comprises 33% of total healthcare spending. In 2017, growth decelerated to 4.6%, or $1.1 trillion, versus 5.6% in 2016. This decline, says CMS, was largely due to slower growth in outpatient visits and steady growth in inpatient days. Physician and clinical services spending slowed to 4.2%, or $694.3 billion, following faster growth of 5.6% in 2016. The tapering off was largely a result of a deceleration of growth in the use—and intensity—of physician and clinical services.
Consumers also saw slowdowns in their spending growth; co-payments, deductibles, and spending not covered by insurance plans grew by 2.6% (to $365.5 billion) in 2017, which was slower than the 4.4% rate of growth in 2016.
Despite these reductions in the pace of spending, CMS points out that healthcare spending’s share of the economy in 2017 (17.9%) was similar to its share in 2016 (18.0%). This phenomenon is attributable to the fact that the 3.9% growth in healthcare pending was slightly slower than the pace of growth in the overall economy (4.2%).
Notably, 2017’s growth in spending on healthcare was slower than recent projections had assumed. A February 2018 paper in Health Affairs2 estimated that spending would grow by 5.5% each year from 2017 to 2026 and would come to represent 19.7% of the economy by 2026.
Reference
1. Martin AB, Hartman M, Washington B, et al. National health care spending in 2017: growth slows to post—Great Recession rates; share of GDP stabilizes [published online December 6, 2018]. Health Aff (Millwood). doi: 10.1377/hlthaff.2018.05085.
2. Cuckler GA, Sisko AM, Poisal JA, et al. National health expenditure projections, 2017-26: despite uncertainty, fundamentals primarily drive spending growth. Health Aff (Millwood). 2018;37(2). doi: 10.1377/hlthaff.2017.1655.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.